Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects - PubMed (original) (raw)
Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects
F M Benes et al. Neuroscience. 1996 Dec.
Abstract
Recent investigations have reported a reduced density of interneurons and an increase of GABAA receptor binding occurring preferentially in layer II of the anterior cingulate cortex of schizophrenic subjects [Benes F.M. et al. (1992) J. Neurosci. 12, 924-929]. Since a reduction in the density of interneurons has also been found in layer II of the prefrontal cortex, this study has sought to determine whether an un-regulation of the GABAA receptor binding activity might also be found in this region of schizophrenics. A high-resolution autoradiographic analysis of bicuculline-sensitive [3H]muscimol (GABAA) receptor binding on individual neuron cell bodies in layers II, III, IV and VI has been applied to Brodmann area 10 from normal controls (n = 16) and schizophrenic (n = 7) subjects. A computer-assisted technique has been used under strictly blind conditions to determine whether differences in binding occur in the schizophrenic group. A significant increase of GABAA receptor binding activity has been observed in layers II, III, V and VI in the schizophrenic group. When the binding is expressed as a density with respect to neuronal cell size, there is a gradient of binding across layers II, III, V and VI, with neuronal cell bodies in layer II having the greatest density of grains. When different subpopulations of neurons distinguished according to size criteria are examined separately, large (pyramidal) neurons show significantly higher binding, particularly in layer II, where it was increased by 90% in schizophrenics. Small (non-pyramidal) cells do not show significant differences in binding in schizophrenics, except in layer VI, where there was a 135% increase. Potential confounding effects from age and post mortem interval do not explain the differences between the two groups, because both young and old schizophrenics, as well as schizophrenics with long and short post mortem intervals, showed increased GABAA receptor binding activity when compared to control cases distinguished in a corresponding fashion. These data suggest that there may be a preferential reduction of inhibitory GABAergic inputs to pyramidal neurons, particularly in layer II of the preferential cortex, in schizophrenia. This change could potentially result in an increased excitatory outflow from the prefrontal area to other cortical regions of the schizophrenic brain. Overall, these results are consistent with the idea that reduced amounts of GABAergic activity in the prefrontal cortex could be related to a perinatal disturbance and could be a potentially important component of the pathophysiology of psychosis.
Similar articles
- Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics.
Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP. Benes FM, et al. J Neurosci. 1992 Mar;12(3):924-9. doi: 10.1523/JNEUROSCI.12-03-00924.1992. J Neurosci. 1992. PMID: 1372045 Free PMC article. - GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls.
Akbarian S, Huntsman MM, Kim JJ, Tafazzoli A, Potkin SG, Bunney WE Jr, Jones EG. Akbarian S, et al. Cereb Cortex. 1995 Nov-Dec;5(6):550-60. doi: 10.1093/cercor/5.6.550. Cereb Cortex. 1995. PMID: 8590827 - Differential distribution of tyrosine hydroxylase fibers on small and large neurons in layer II of anterior cingulate cortex of schizophrenic brain.
Benes FM, Todtenkopf MS, Taylor JB. Benes FM, et al. Synapse. 1997 Jan;25(1):80-92. doi: 10.1002/(SICI)1098-2396(199701)25:1<80::AID-SYN10>3.0.CO;2-2. Synapse. 1997. PMID: 8987151 - Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics.
Bachus SE, Hyde TM, Herman MM, Egan MF, Kleinman JE. Bachus SE, et al. J Psychiatr Res. 1997 Mar-Apr;31(2):233-56. doi: 10.1016/s0022-3956(96)00041-6. J Psychiatr Res. 1997. PMID: 9278188 Review. - When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits.
Garey L. Garey L. J Anat. 2010 Oct;217(4):324-33. doi: 10.1111/j.1469-7580.2010.01231.x. J Anat. 2010. PMID: 20408906 Free PMC article. Review.
Cited by
- Cannabinoids for the treatment of schizophrenia? A balanced neurochemical framework for both adverse and therapeutic effects of cannabis use.
Coulston CM, Perdices M, Henderson AF, Malhi GS. Coulston CM, et al. Schizophr Res Treatment. 2011;2011:501726. doi: 10.1155/2011/501726. Epub 2010 Jul 27. Schizophr Res Treatment. 2011. PMID: 22937266 Free PMC article. - Dysfunctional GABAergic inhibition in the prefrontal cortex leading to "psychotic" hyperactivation.
Tanaka S. Tanaka S. BMC Neurosci. 2008 Apr 25;9:41. doi: 10.1186/1471-2202-9-41. BMC Neurosci. 2008. PMID: 18439259 Free PMC article. - Reduced _γ_-Aminobutyric Acid and Glutamate+Glutamine Levels in Drug-Naïve Patients with First-Episode Schizophrenia but Not in Those at Ultrahigh Risk.
Wang J, Tang Y, Zhang T, Cui H, Xu L, Zeng B, Li Y, Li G, Li C, Liu H, Lu Z, Zhang J, Wang J. Wang J, et al. Neural Plast. 2016;2016:3915703. doi: 10.1155/2016/3915703. Epub 2016 Nov 28. Neural Plast. 2016. PMID: 28003912 Free PMC article. - GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon.
Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M, Zhang X, Costa E. Guidotti A, et al. Psychopharmacology (Berl). 2005 Jul;180(2):191-205. doi: 10.1007/s00213-005-2212-8. Epub 2005 Apr 28. Psychopharmacology (Berl). 2005. PMID: 15864560 Review. - Amygdalocortical circuitry in schizophrenia: from circuits to molecules.
Benes FM. Benes FM. Neuropsychopharmacology. 2010 Jan;35(1):239-57. doi: 10.1038/npp.2009.116. Neuropsychopharmacology. 2010. PMID: 19727065 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical